E-LIB Suche - Ergebnisse für: Locke, Frederick

1

A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Ve..:

Locke, Frederick L. ; Ray, Mark ; Hasegawa, Ken...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S366-S367 , 2024

Link: https://doi.org/10.1016/..

2

Outcomes of Haploidentical Stem Cell Transplant Recipients ..:

Yepes, Amanda ; Faramand, Rawan G ; Bejanyan, Nelli...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S439 , 2024

Link: https://doi.org/10.1016/..

3

Impact of Renally Adjusted Methotrexate Dosing on Safety an..:

Emanuel, Natasha ; Gonzalez, Rebecca ; Perkins, Janelle...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S271 , 2024

Link: https://doi.org/10.1016/..

4

Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (..:

Caimi, Paolo ; Schuster, Stephen J. ; Nastoupil, Loretta J....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S188-S189 , 2024

Link: https://doi.org/10.1016/..

5

Axicabtagene ciloleucel vs standard of care in second-line ..:

Locke, Frederick L. ; Oluwole, Olalekan O. ; Kuruvilla, John...
Blood. 143 (2024) 24 - p. 2464-2473 , 2024

Link: https://doi.org/10.1182/..

6

CAR T cell Toxicities: Bedside to Bench - How Novel Toxicit..:

Perna, Fabiana ; Parekh, Samir ; Diorio, Caroline...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

7

Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd..:

Pidala, Joseph A. ; Betts, Brian C. ; Schell, Michael...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S27-S28 , 2024

Link: https://doi.org/10.1016/..

8

A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Ve..:

Locke, Frederick L. ; Hasegawa, Ken ; Patel, Anik R....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S367-S368 , 2024

Link: https://doi.org/10.1016/..

9

Autologous Hematopoietic Cell Transplantation Consolidation..:

Zhang, Yumeng ; Rose, Ashley ; Khadka, Sushmita...
Transplantation and Cellular Therapy. , 2024

Link: https://doi.org/10.1016/..

10

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient ..:

Oluwole, Olalekan O. ; Dholaria, Bhagirathbhai ; Knight, Tristan E....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. 131-142 , 2024

Link: https://doi.org/10.1016/..

11

Identification of Pre-Treatment Clinical Risk Factors Predi..:

Geethakumari, Praveen Ramakrishnan ; Wudhikarn, Kitsada ; Jain, Michael D....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S358-S359 , 2024

Link: https://doi.org/10.1016/..

12

Evaluation of Outpatient Administration of Ciltacabtagene A..:

Waqar, Syed Hamza Bin ; Hansen, Doris K ; Freeman, Ciara Louise...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S388 , 2024

Link: https://doi.org/10.1016/..

13

Real-World Tisagenlecleucel Outcomes in Richter-Transformed..:

Shadman, Mazyar ; Frigault, Matthew J. ; Foley, Stephen Ronan...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S189-S190 , 2024

Link: https://doi.org/10.1016/..

14

Cost-effectiveness of axicabtagene ciloleucel versus tisage..:

Oluwole, Olalekan O. ; Ray, Markqayne D. ; Davies, Neil...
Journal of Medical Economics. 27 (2024) 1 - p. 230-239 , 2024

Link: https://doi.org/10.1080/..

15

Simple Score of Albumin and CRP Predicts High-Grade Toxicit..:

Akhtar, Othman S. ; Modi, Karnav ; Kim, Jongphil...
Transplantation and Cellular Therapy. 30 (2024) 3 - p. 283.e1-283.e10 , 2024

Link: https://doi.org/10.1016/..